Jean-Luc Villeval

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2664087/publications.pdf Version: 2024-02-01



IEAN-LUC VILLEVAL

#	Article	IF	CITATIONS
1	Lessons from mouse models of MPN. International Review of Cell and Molecular Biology, 2022, 366, 125-185.	3.2	2
2	PPARÎ ³ agonists promote the resolution of myelofibrosis in preclinical models. Journal of Clinical Investigation, 2021, 131, .	8.2	4
3	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by ${\sf IFN}\hat{\sf I}\pm$ in myeloproliferative neoplasms. Blood, 2021, 138, 2231-2243.	1.4	25
4	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. Journal of Experimental Medicine, 2021, 218, .	8.5	22
5	Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. Nature Communications, 2020, 11, 4886.	12.8	27
6	Megakaryocytes tame erythropoiesis with TGFβ1. Blood, 2020, 136, 1016-1017.	1.4	5
7	Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. Journal of Clinical Investigation, 2020, 130, 2630-2643.	8.2	42
8	Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfbâ€positive hematopoietic cells. Journal of Thrombosis and Haemostasis, 2019, 17, 827-840.	3.8	24
9	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood, 2016, 127, 1317-1324.	1.4	220
10	Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood, 2014, 124, 1136-1145.	1.4	51
11	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood, 2013, 122, 1464-1477.	1.4	122
12	High Thrombopoietin Production by Hematopoietic Cells Induces a Fatal Myeloproliferative Syndrome in Mice. Blood, 1997, 90, 4369-4383.	1.4	235